Furthermore, reactivating CD8+ T cell immunity against tumours using targeted checkpoint blockade therapy has revolutionised cancer treatments and patient outcomes, subsequently leading to the Nobel Prize in Physiology and Medicine in 2018 being awarded to James Allison and Tasuku Honjo for their discovery of CTLA-4 (cytotoxic lymphocyte protein 4) and PD-1 (programmed cell death protein 1) [12,13]. The gene discussed is CD8A; the disease is neoplasm.